Lone B. Pedersen

Copenhagen, 2100, Denmark

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Exploring the Prognostic Potential of circSCORE in Patients with Relapsed/Refractory Mantle Cell Lymphoma.

Exploring the Prognostic Potential of circSCORE in Patients with Relapsed/Refractory Mantle Cell Lymphoma.

Journal: Genes
Published: April 04, 2025

Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma.

Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma.

Journal: Blood advances
Published: January 02, 2025

MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.

MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.

Journal: Blood advances
Published: October 12, 2023

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV.

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV.

Journal: Frontiers in oncology
Published: August 19, 2022

Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL.

Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL.

Journal: Leukemia
Published: June 17, 2022

An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma.

An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma.

Journal: Oncoimmunology
Published: September 25, 2021

Chronic lymphocytic leukaemia clones are detectable decades before diagnosis.

Chronic lymphocytic leukaemia clones are detectable decades before diagnosis.

Journal: British journal of haematology
Published: July 22, 2021

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3.

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3.

Journal: HemaSphere
Published: June 27, 2020

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.

Journal: Blood
Published: May 14, 2020

Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL.

Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL.

Journal: Blood
Published: March 18, 2020

The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome.

The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 19, 2018

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.

Journal: Haematologica
Published: May 26, 2018
Showing 1-12 of 29

Last Updated: 09/26/2026